BCGM Wealth Management LLC Makes New Investment in Gilead Sciences, Inc. $GILD

BCGM Wealth Management LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 11,746 shares of the biopharmaceutical company’s stock, valued at approximately $1,442,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of GILD. Trivium Point Advisory LLC increased its position in Gilead Sciences by 1.1% in the third quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock worth $813,000 after purchasing an additional 83 shares during the last quarter. Binnacle Investments Inc grew its stake in shares of Gilead Sciences by 11.8% in the 3rd quarter. Binnacle Investments Inc now owns 785 shares of the biopharmaceutical company’s stock worth $87,000 after buying an additional 83 shares in the last quarter. Hemington Wealth Management grew its stake in shares of Gilead Sciences by 9.3% in the 3rd quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 85 shares in the last quarter. Ignite Planners LLC increased its holdings in shares of Gilead Sciences by 1.1% in the 3rd quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock worth $880,000 after buying an additional 86 shares during the last quarter. Finally, Archer Investment Corp lifted its holdings in shares of Gilead Sciences by 1.2% in the 2nd quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock valued at $807,000 after acquiring an additional 87 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $144.79, for a total value of $1,447,900.00. Following the transaction, the chief executive officer directly owned 642,308 shares in the company, valued at approximately $92,999,775.32. This represents a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the transaction, the director owned 8,920 shares of the company’s stock, valued at $1,101,620. The trade was a 35.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 309,280 shares of company stock worth $44,068,850. Corporate insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on GILD shares. Cantor Fitzgerald raised their price objective on Gilead Sciences from $135.00 to $155.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Morgan Stanley raised their price target on Gilead Sciences from $150.00 to $171.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Wells Fargo & Company lifted their price objective on shares of Gilead Sciences from $150.00 to $165.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Jefferies Financial Group initiated coverage on shares of Gilead Sciences in a research note on Tuesday, March 10th. They issued a “buy” rating and a $180.00 target price on the stock. Finally, The Goldman Sachs Group lifted their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a research note on Thursday, January 8th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $157.62.

Gilead Sciences Stock Down 2.8%

Shares of GILD opened at $137.21 on Friday. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $157.29. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The stock has a fifty day simple moving average of $142.69 and a two-hundred day simple moving average of $127.77. The company has a market capitalization of $170.34 billion, a PE ratio of 20.27, a price-to-earnings-growth ratio of 1.85 and a beta of 0.37.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. During the same quarter in the previous year, the company posted $1.90 EPS. The company’s revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.4%. The ex-dividend date is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.45%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.